Last updated: April 26, 2026
Teva Pharmaceuticals USA, Inc. v. Mylan Pharmaceuticals Inc. (1:14-cv-00167): Litigation Summary and Patent/Entitlement Analysis
What case is this and what is the procedural posture?
Caption: Teva Pharmaceuticals USA, Inc. v. Mylan Pharmaceuticals Inc.
Court & docket: U.S. District Court (case no. 1:14-cv-00167)
Parties (as stated in the caption): Teva Pharmaceuticals USA, Inc. (plaintiff) vs. Mylan Pharmaceuticals Inc. (defendant)
This is a patent infringement dispute tied to U.S. generic drug market entry through the Hatch-Waxman framework (commonly litigated via ANDA-specific infringement claims). The docket number and party names align with a set of Orange Book driven IP claims typical of ANDA litigation.
What patent issues does the case turn on?
The factual record needed to identify the specific asserted patents, claims at issue, and final rulings for docket 1:14-cv-00167 is not present in the input provided. A litigation summary without the asserted patent list and the court’s disposition would be incomplete and risks generating incorrect claim-level or entitlement-level conclusions.
Accordingly, a complete, accurate patent litigation analysis cannot be produced from the information supplied.
What is the litigation outcome (judgment, dismissal, settlement, or claim construction posture)?
No outcome information is provided (no settlement date, no dismissal order, no judgment, no appeal status, and no claim construction record). Without the disposition, it is not possible to map:
- which patents survived,
- which claims were found infringed or invalid,
- whether the court granted a preliminary injunction or denied it,
- whether the case settled before final judgment,
- or whether any aspect of the judgment is appealable.
What would be the actionable business takeaways if the record were available?
For ANDA-style cases, the decision typically informs:
- Market entry timing (launch date and potential design-around paths)
- Regulatory leverage (Orange Book listings and use codes impacted)
- Commercial risk (likelihood of injunction or enforceable judgment)
- Design-around feasibility (whether claim scope is narrow or broad)
- Litigation posture trends (court’s approach to claim construction and invalidity)
But applying these to 1:14-cv-00167 requires the missing docket-specific holdings.
Key Facts Table (What can be stated from provided input only)
| Item |
Value |
| Plaintiff |
Teva Pharmaceuticals USA, Inc. |
| Defendant |
Mylan Pharmaceuticals Inc. |
| Case number |
1:14-cv-00167 |
| Court |
U.S. District Court |
| Subject (type) |
Patent litigation tied to generic market entry (inferred from Hatch-Waxman context, but not specific) |
| Asserted patents / claims |
Not provided |
| Claim construction rulings |
Not provided |
| Final disposition |
Not provided |
| Settlement terms / dates |
Not provided |
Why can’t a full patent-entitlement analysis be completed from the supplied data?
A credible patent litigation summary must include at least one of the following:
- asserted patent numbers and relevant claim chart outcomes,
- the court’s final decision (or dismissal/consent judgment),
- key orders (claim construction, PI ruling, summary judgment),
- or a docket event list that records the case outcome.
None of that information appears in the prompt content. Under strict accuracy constraints, producing a detailed analysis without those inputs would risk fabricating specifics.
Key Takeaways
- The provided information identifies the parties and docket number: Teva vs. Mylan, 1:14-cv-00167.
- A complete litigation summary and patent entitlement analysis requires asserted patent details and the court’s disposition.
- No asserted patents, claim construction results, or final outcome are included in the input, preventing an accurate case-specific analysis.
FAQs
1) Who sued whom in 1:14-cv-00167?
Teva Pharmaceuticals USA, Inc. sued Mylan Pharmaceuticals Inc.
2) What court has jurisdiction over 1:14-cv-00167?
It is a U.S. District Court matter, identified by docket number 1:14-cv-00167.
3) What patents were asserted?
The asserted patents are not included in the provided input.
4) Did the case end in judgment or settlement?
The case disposition is not included in the provided input.
5) What is the relevance to generic launch timing?
For ANDA-style litigation, outcomes can affect launch timing and enforceable rights, but the specific impact for 1:14-cv-00167 cannot be derived from the provided data.
References
- (No citable sources provided in the input.)
